Axcella Therapeutics (AXLA) Posts Interim Data from Phase 2b EMMPACT Study of AXA1125 in NASH https://www.streetinsider.com/Corporate+News/Axcella+Therapeutics+%28AXLA%29+Posts+Interim+Data+from+Phase+2b+EMMPACT+Study+of+AXA1125+in+NASH/20641024.html